Mimedx Group Inc(MDXG) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 11 at 4:14 PM ET (Korea 9/12 05:14)
Full metrics table
| Index | RUT | P/E | 115.99 | EPS (ttm) | 0.04 | Insider Own | 21.58% | Shs Outstand | 145.7M | Perf Week | 3.16% |
| Market Cap | 0.67B | Forward P/E | 48.62 | EPS next Y | 161.64% | Insider Trans | - | Shs Float | 114.3M | Perf Month | 6.78% |
| Enterprise Value | 0.55B | PEG | - | EPS next Q | -0.01 | Inst Own | 57.66% | Short Float | 8.21% | Perf Quarter | 23.85% |
| Income | 0.01B | P/S | 1.88 | EPS this Y | -147.66% | Inst Trans | -0.82% | Short Ratio | 7.36 | Perf Half Y | 4.34% |
| Sales | 0.36B | P/B | 3.08 | EPS next 5Y | -12.19% | ROA | 2.18% | Short Interest | 9.38M | Perf YTD | -32.5% |
| Book/sh | 1.48 | P/C | 4.9 | EPS past 3/5Y | - | ROE | 2.88% | 52W High | -42.66% ($7.97) | Perf Year | -35.99% |
| Cash/sh | 0.93 | P/FCF | 14.97 | Sales past 3/5Y | 16.05% 11.02% | ROIC | 2.69% | 52W Low | 51.07% ($3.03) | Perf 3Y | -44% |
| Dividend Est. | - | EV/EBITDA | 26.82 | EPS Y/Y TTM | -80.69% | Gross Margin | 78.61% | Volatility(W/M) | 4.83% 3.95% | Perf 5Y | -70.57% |
| Dividend TTM | - | EV/Sales | 1.54 | Sales Y/Y TTM | -2.36% | Oper. Margin | 2.46% | ATR (14) | 0.19 | Perf 10Y | -44.87% |
| Dividend Ex-Date | - | Quick Ratio | 4.79 | EPS Q/Q | -255.9% | Profit Margin | 1.76% | RSI (14) | 57.63 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 5.33 | Sales Q/Q | -34.73% | SMA20 | 2.64% ($4.45) | Beta | 1.17 | Target Price | $7.4 |
| Payout | - | Debt/Eq | 0.08 | Earnings | 2026/7/29 | SMA50 | 5.91% ($4.31) | Rel Volume | 0.69 | Prev Close | $4.6 |
| Employees | 808 | LT Debt/Eq | 0.07 | EPS/Sales Surpr. | -102.02% 1.42% | SMA200 | -2.16% ($4.67) | Avg Volume(3M) | 1.27M | Price | $4.57 |
| IPO | 2007/8/22 | Option/Short | Yes/Yes | Trades | 5056 | Volume | 877,122 | Change | -0.65% |
Company
MDXG is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
🩹 MiMedx Group (MDXG) is a US healthcare company that develops and sells regenerative biomaterials and allografts derived from human placental tissue. It supplies patented regenerative biologics products such as EpiFix and AmnioFix for the treatment of chronic wounds, surgery, and sports medicine/orthopedics, and has established itself as a specialist in the advanced wound care market.
Over the past 1 year, roughly in the middle
43% below its 1-year high.
MDXG makes money exceptionally well
2.46% of revenue is kept as operating profit.
Tap to view numbers
Growth is moderate
Earnings are expected to grow by -147.7% this year.
Tap to view numbers
But it is not cheap
Trading at 116.0 times earnings.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Would have changed by -44.0% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 57.7%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
SVAL 0.00%
QQQS 0.00%
SQLV 0.00%
XBI 0.00%
SFLO 0.00%It ranks #4 in the industry
Based on market cap of $666M.
MDXG $666M PER 116.0
VRTX $131B PER 30.0
REGN $80B PER 19.3
ARGX $62B PER 37.5
FAQ
What kind of company is MDXG?
MDXG belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of MDXG?
The market cap of MDXG is approximately $666M, ranking 2,985 within its sector.
What is the P/E ratio of MDXG?
MDXG has a P/E ratio of approximately 116.0x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for MDXG?
MDXG has recorded a 52-week high of $7.97 and a low of $3.03.
